A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStim Combined With Cryoablation to a Physician's Choice Combined With Cryoablation in 3rd Line Treatment for Metastatic Colorectal Cancer

Trial Profile

A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStim Combined With Cryoablation to a Physician's Choice Combined With Cryoablation in 3rd Line Treatment for Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Immunovative Therapies
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
    • 07 Aug 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top